| Name | Title | Contact Details |
|---|
Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.
AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitro Diagnostics is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vision Innovation Partners unites the mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of a leading middle-market private equity firm.